Graves' Disease

Active Ophthalmopathy Benefits From Teprotumumab Treatment

Active Ophthalmopathy Benefits From Teprotumumab Treatment

Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.

Rituximab Bests Methylprednisolone in Graves' Orbitopathy

Rituximab Bests Methylprednisolone in Graves' Orbitopathy

In a randomized, double-blind study, Rituximab was more effective in treating Graves' orbitopathy than intravenous methylprednisolone.

Graves' Ophthalmopathy Risk Decreased With Thyroidectomy, Statin Use

Graves' Ophthalmopathy Risk Decreased With Thyroidectomy, Statin Use

Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves' disease.

Thyroid Antibody Levels Not Predictive of Clinical Manifestations of Graves' Disease

Thyroid Antibody Levels Not Predictive of Clinical Manifestations of Graves' Disease

By

Thyroid-specific autoantibody levels did not predict clinical features of Graves' disease, including ophthalmopathy or goiter.

Methimazole Exposure Linked to Higher Pregnancy Complication Rate

Methimazole Exposure Linked to Higher Pregnancy Complication Rate

By

Women should likely discontinue methimazole during pregnancy to prevent complications.

Rituximab Not Effective in Graves' Orbitopathy

Rituximab Not Effective in Graves' Orbitopathy

Rituximab did not perform better than a placebo in treating Graves' orbitopathy in a randomized controlled trial.

Sign Up for Free e-Newsletters

CME Focus